Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Assets (2016 - 2026)

Ekso Bionics Holdings has reported Assets over the past 14 years, most recently at $20.1 million for Q4 2025.

  • On a quarterly basis, Assets fell 24.54% to $20.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.1 million, a 24.54% decrease, with the full-year FY2025 number at $20.1 million, down 24.54% from a year prior.
  • Assets reached $20.1 million in Q4 2025 per EKSO's latest filing, down from $21.7 million in the prior quarter.
  • The five-year high for Assets was $56.5 million in Q1 2021, with the low at $20.1 million in Q4 2025.
  • The 5-year median for Assets is $32.6 million (2023), against an average of $35.5 million.
  • Peak YoY movement for Assets: soared 233.47% in 2021, then decreased 29.3% in 2023.
  • Tracing EKSO's Assets over 5 years: stood at $49.2 million in 2021, then fell by 16.81% to $40.9 million in 2022, then decreased by 29.3% to $28.9 million in 2023, then decreased by 7.84% to $26.7 million in 2024, then fell by 24.54% to $20.1 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $20.1 million, $21.7 million, and $23.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.